Submitted by Anonymous (not verified) on 5 October 2026 - 9:30
Human medicines European public assessment report (EPAR): Opdualag, relatlimab,nivolumab, Date of authorisation: 15/09/2022, Revision: 10, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Opdualag, relatlimab,nivolumab, Date of authorisation: 15/09/2022, Revision: 10, Status: Authorised